# Protective Effect of EECP Against Negative Inflammatory Response and Organ Dysfunction After Cardiovascular Surgery

Study · id `cardio:ct-nct06728605` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06728605](<https://clinicaltrials.gov/study/NCT06728605>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT06728605

Browse, organ or system: Heart  
Browse, condition area: Acute care and long-term living  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 400 participants.

## Technical summary

Registry record NCT06728605. Randomized; quadruple masking; primary purpose prevention. Start 2025-12-31 (anticipated); primary completion 2025-12-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose prevention
- Phase: Not applicable
- Enrolled: 400 participants (planned count; ClinicalTrials.gov record NCT06728605, source copy `cardio:ctgov-nct06728605-2024-12-11`, retrieved 2026-10-31)
- Planned start: 2025-12-31 (anticipated) (ClinicalTrials.gov record NCT06728605, source copy `cardio:ctgov-nct06728605-2024-12-11`, retrieved 2026-10-31)
- Primary completion: 2025-12-31 (anticipated) (ClinicalTrials.gov record NCT06728605, source copy `cardio:ctgov-nct06728605-2024-12-11`, retrieved 2026-10-31)
- Completion: 2025-12-31 (anticipated) (ClinicalTrials.gov record NCT06728605, source copy `cardio:ctgov-nct06728605-2024-12-11`, retrieved 2026-10-31)
- Countries: China (ClinicalTrials.gov record NCT06728605, source copy `cardio:ctgov-nct06728605-2024-12-11`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06728605-2024-12-11`, retrieved 2026-10-31)

## The registry's words

- Brief title: Protective Effect of EECP Against Negative Inflammatory Response and Organ Dysfunction After Cardiovascular Surgery
- Acronym: PANDA
- Condition: Coronary Heart Disease (CHD)
- Condition: Cardio-pulmonary Bypass
- Condition: Congestive Heart Failure Chronic
- Condition: Cardiogenic Shock Acute
- Intervention (Device): Enhanced External Counterpulsation (EECP)
- Intervention (Device): Sham Comparator
- Lead sponsor: Nanjing Medical University
- Lead sponsor class: OTHER
- Collaborator: The First Affiliated Hospital with Nanjing Medical University
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Cardiogenic shock (`cardio:cardiogenic-shock`)
- Registry lists this organization as the lead sponsor: Nanjing Medical University (`cardio:org-nanjing-medical-university`)
- Registry lists this organization as a collaborator: The First Affiliated Hospital with Nanjing Medical University (`cardio:org-the-first-affiliated-hospital-with-nanjing-medical-898271`)

## Provenance

Content hash: 83db27047bd58b65717583b82b8d394d834ba18614c7e2ce3c7892aa8b714f3c
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
